报名：首届全球眼科大会 | 议程更新 报名：首届全球心血管大会 | 奖项申报 报名：首届全球骨科大会 | 奖项评选 合作伙伴征集：2025全球手术机器人大会 2025年4月1日，国家药品监督管理局批准了 上海商阳医疗科技有限公司 的 "心脏脉冲电场消融设备" （ 国械注准20253010702）和 "一次性使用磁电定位心脏 脉冲电场消融导管" （ 国械注准20253010703），以及 天津市鹰泰利安康医疗科技有限责任公司 的 "心脏脉冲电场消融仪" （ 国械注准20253010705）和 "一 次性使用心脏脉冲电场消融导管" （ 国械注准20253010704） 创新产品注册申请。 截至目前，我国上市的创新医疗器械累计 338项 。 | 索引号 | XZXK-2025-174 主题分类 | | --- | --- | | 标题 | 心脏脉冲电场消融设备和一次性使用磁电定位心脏脉冲电场消融导管创新产品获批上市 | | 发布日期 | 2025-04-01 | 产品介绍 # 商阳医疗： "心脏脉冲电场消融设备"和"一次性使用磁电定位心脏脉冲电场消融导管" 产品介绍 心脏脉冲电场消融设备由 主机、电源线、脚踏开关、 ...

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [2] Core Views - The company's performance in 2024 met expectations, with a revenue of 2,065.80 million yuan, a year-on-year increase of 25.18%, and a net profit attributable to the parent company of 673.48 million yuan, up 26.14% year-on-year [4][8] - The company has maintained a net profit growth rate of over 25% for several consecutive years, indicating strong growth potential [4] - The domestic market's product admission rate has continued to improve, with over 150 new hospitals adopting the company's electrophysiology products and a more than 100% increase in the number of three-dimensional electrophysiology surgeries performed [5] - The company is actively expanding its overseas market and enhancing its internal governance structure, focusing on revenue growth, cost control, and quality improvement [6] - Significant R&D progress has been made, with key products approved for market release, including a disposable cardiac pulsed field ablation catheter, which is expected to create new revenue growth opportunities in 2025 [7][8] Financial Summary - The company is projected to achieve revenues of 2,066 million yuan, 2,521 million yuan, and 2,996 million yuan for 2024, 2025, and 2026 respectively, with net profits of 673 million yuan, 922 million yuan, and 1,092 million yuan for the same years [8][11] - The gross profit margin is expected to improve from 72.6% in 2024 to 77.7% in 2026, indicating enhanced profitability [11] - The company's earnings per share (EPS) are forecasted to be 6.92 yuan, 9.47 yuan, and 11.22 yuan for 2024, 2025, and 2026 respectively [11]